Compare Huntington Bancshares Incorporated (HBAN) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Huntington Bancshares Incorporated trades at $15.18 (market cap $30.79B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Huntington Bancshares Incorporated is far larger — about 31.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Huntington Bancshares Incorporated pays a 4.07% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Bancshares Incorporated for 52 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HBAN | MRVI | |
|---|---|---|
Market Cap | $30.79B | $972.90M |
Volume | 16,522,211 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $19.27 | $9.00 |
52-Week Low | $15.02 | $2.83 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | $49.31B | $1.08B |
Dividend Yield | 4.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $15.10, down 1.95% amid bearish technical signals and recent earnings volatility. The stock shows mixed fundamentals with a P/E of 11.72 and ROE of 9.23%, while revenue grew to $8.13B in 2025. Recent news highlights margin pressures from higher interest rates and a reduced 2027 outlook, though the company maintains shareholder returns through dividends and buybacks.
HBAN presents a cautious near-term outlook with analyst consensus at $19.60 (30% upside potential) but faces headwinds from net interest margin compression. Investment opportunity lies in valuation discount to peers, while risks include prolonged rate pressures and execution challenges in loan growth. The balanced analyst rating (47% Buy, 47% Hold) reflects uncertainty around timing of recovery.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
